跳轉至內容
Merck
全部照片(1)

重要文件

EMU154511

Sigma-Aldrich

MISSION® esiRNA

targeting mouse Erbb3

登入查看組織和合約定價
全部照片(1)

About This Item

分類程式碼代碼:
41105324
NACRES:
NA.51

描述

Powered by Eupheria Biotech

品質等級

100

產品線

MISSION®

形狀

lyophilized powder

esiRNA cDNA 標靶序列

CCCCGTGAAGTCAAGAATTTCCACCTTTTCTCAAACAAAAAACCATTTCTTTGACACATTTGAATTAATAGCAGGACTTGCCCTTTGGGCCCATTCTTAGGTAAGATGAGGGTCTTTGAGCACAAGTACTATGAGATCTGTCAGTCAATCTAATAACCAGGCAGGTAATTAAGTGGCTCAAGAGCAAATAGGTTATTCAGTGCGGGTGTACCAGGCAGAGATGATTCATCTACCAAGTGGAACAGGAGAGGCCGGCTGTGATTTCATCGTGCTATTCAGAATGGGTACTATGTAAACTGTAAGGATTATTTATTTCAGGAACTTGTCACTCAGCATGTTTCAGATGACAGTTGACCACAGGTTACTAAAACTGTGGACAGCAAAACCTCAGAAAATGGGGAATTGAGCCTTGAAGAAGCAAAGCCACAGGTCCAGGATTCAAAATCCTCCCAATTCCCATGCCTGTGATTTAACTATAAAGTGTATGTGTGTGTGTGTAAAGCCGGGCCT

Ensembl | 小鼠類登錄號

ENSMUSG00000018166

NCBI登錄號

NM_010153

運輸包裝

ambient

儲存溫度

−20°C

基因資訊

mouse ... ERBB3(13867) , Erbb3(13867)

一般說明

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

法律資訊

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

10 - Combustible liquids

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

C He et al.
Oncogene, 34(50), 6040-6054 (2015-03-24)
Mechanisms underlying ovarian cancer initiation and progression are unclear. Herein, we report that the Yes-associated protein (YAP), a major effector of the Hippo tumor suppressor pathway, interacts with ERBB signaling pathways to regulate the initiation and progression of ovarian cancer.
Maicol Mancini et al.
Science signaling, 8(379), ra53-ra53 (2015-06-04)
Despite initial responses to targeted kinase inhibitors, lung cancer patients presenting with primary epidermal growth factor receptor (EGFR) mutations acquire resistance, often due to a second-site mutation (T790M). However, clinical trials found no survival benefits in patients treated with a

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務